Replies to post #126845 on Biotech Values

[DewDiligence]

Annual growth could slow or perhaps even drop if multiple copaxone generics are approved.

The overall size of the US Copaxone market (branded + generic) probably won’t change much from the approval of one or two generics. The average selling price will presumably come down a little compared to what it would be with a monopoly, but this will be offset to some degree by an increase in unit volume.